Prosulpride is an aminosulfonylbenzamide derivative with potent neuroleptic activity. Prosulpride selectively blocks the presynaptic dopaminergic receptors and antagonize apomorphine-induced stereotyped behavior, circling behavior, climbing behavior, increased motor activity and some other apomorphine-induced effects related to stimulation of postsynaptic dopaminergic receptors.

Pruvanserin (EMD 281014, LY-2422347) is a selective serotonin 5-HT2A receptor antagonist. Pruvanserin was originated by Merck KGaA. Eli Lilly had been developing pruvanserin, under a global licence from Merck KGaA, for the treatment of primary insomnia and major depressive disorder. Phase II trials were completed in the US, Hungary and Spain. However, development appears to have been discontinued.

Pumosetrag is a novel, orally active and selective 5-HT 3 agonist. It is a partial agonist in rats and guinea-pig and a full agonist in the mouse, suggesting important species differences in 5-HT3 receptor structure. Pumosetrag had been in phase II clinical trials for the treatment of gastroesophageal reflux disease and irritable bowel syndrome. No serious adverse events were reported. Diarrhea was not more common on the drug and only one subject experienced pruritus. All researches on this drug candidate are discontinued.

Quatacaine is a methylpropionanilide derivative patented by Tanabe Seiyaku Co., Ltd. As local anaesthetic.

Profexalone is an oxazolidinone derivative patented by Delalande S. A. as anticonvulsive, muscle-relaxant, antidepressive, anti-inflammatory, and analgesic compound.

Flupimazine was invented as a neuroleptic agent. However, information about the current use of this drug is not available.

Draquinolol is a cardioselective beta-adrenoceptor antagonist with a long duration of action in vivo. The long duration of action of draquinolol in vivo is due to the formation of a tight complex with beta 1-adrenoceptors. Draquinolol reduced an exercise tachycardia.

Doxpicomine is the hydrochloride salt of l-3[(dimethylamino)-(m-dioxan-5-yl)methyl]pyridine, a derivative of substituted 1,3 dioxanes. Its analgesic effect appears to be mediated centrally through opiate-like receptors. Preclinical animal studies revealed analgesic activity and duration of action of the same order as that of meperidine and codeine when administered subcutaneously and of codeine but of shorter duration when administered orally. The analgesic effects were reversed by naloxone. The drug did not reduce or antagonize the analgesic effect of morphine. Drowsiness is an expected response to effective analgesics. It was the foremost side effect observed but was of short duration and minimal intensity and did not interfere with the postoperative regimen of coughing, deep breathing, and early ambulation. Nausea and vomiting were not reported after doxpicomine.

FLUMEXADOL is a non-opioid analgesic. Its prodrug OXAFLOZANE was used as an antidepressant in France till 2004.

Indanidine is a selective and effective α2-antagonist, α1-partial agonist patented by pharmaceutical company Siegfried A.-G as a low toxic compound with direct hypotensive action. Indanidine does not penetrate the blood-brain barrier, does not induce drug-metabolizing enzymes in the liver, does not cause behavioral changes.